Thyroid dysfunctions due to immune checkpoint inhibitors: A review
| dc.contributor.author | Sabbagh, Rawaa El | |
| dc.contributor.author | Azar, Nadim S. | |
| dc.contributor.author | Eid, Assaad A. | |
| dc.contributor.author | Azar, Sami T. | |
| dc.contributor.department | Internal Medicine | |
| dc.contributor.department | Anatomy, Cell Biology, and Physiological Sciences | |
| dc.contributor.department | Division of Endocrinology and Metabolism | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:59:46Z | |
| dc.date.available | 2025-01-24T11:59:46Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Aim: Immune checkpoint inhibitors are anti-cancer drugs associated with adverse events that result from releasing the immune system against self-antigens while attacking cancer cells. Thyroid dysfunctions are among the most common associated adverse events. Materials and Methods: We conducted a systematic search of the literature in 2 databases: PubMed and Medline. Articles that reported thyroid adverse events of immune checkpoint inhibitors were reviewed. Thyroid disorders include hyperthyroidism and hypothyroidism and are most commonly seen with programmed cell death protein 1 and programmed death-ligand 1 inhibitors. Conclusions: Thyroid disorders are common side effects seen with check point inhibitors and are treated, depending on the clinical situation, by adequate hormonal replacement, thionamides, corticosteroids or observation only. The use of high dose corticosteroids has not been established as a treatment of thyroid toxicities. Thyroid function tests screening should be a part of baseline laboratory testing of all patients undergoing treatment with immune checkpoint inhibitors. © 2020, Dove Medical Press Ltd. All rights reserved. | |
| dc.identifier.doi | https://doi.org/10.2147/IJGM.S261433 | |
| dc.identifier.eid | 2-s2.0-85096211302 | |
| dc.identifier.uri | http://hdl.handle.net/10938/31387 | |
| dc.language.iso | en | |
| dc.publisher | Dove Medical Press Ltd | |
| dc.relation.ispartof | International Journal of General Medicine | |
| dc.source | Scopus | |
| dc.subject | Anti-pd1 | |
| dc.subject | Anti-pdl1 | |
| dc.subject | Immune check point inhibitors | |
| dc.subject | Thyroid dysfunction | |
| dc.subject | Atezolizumab | |
| dc.subject | Avelumab | |
| dc.subject | Cemiplimab | |
| dc.subject | Corticosteroid | |
| dc.subject | Cytotoxic t lymphocyte antigen 4 | |
| dc.subject | Durvalumab | |
| dc.subject | Immune checkpoint inhibitor | |
| dc.subject | Levothyroxine | |
| dc.subject | Nivolumab | |
| dc.subject | Pembrolizumab | |
| dc.subject | Programmed death 1 ligand 1 | |
| dc.subject | Programmed death 1 receptor | |
| dc.subject | Thionamide | |
| dc.subject | Clinical feature | |
| dc.subject | Clinical observation | |
| dc.subject | Disease association | |
| dc.subject | Drug classification | |
| dc.subject | Drug indication | |
| dc.subject | Drug overdose | |
| dc.subject | Hormone substitution | |
| dc.subject | Human | |
| dc.subject | Hyperthyroidism | |
| dc.subject | Hypothyroidism | |
| dc.subject | Incidence | |
| dc.subject | Myxedema | |
| dc.subject | Pathogenesis | |
| dc.subject | Patient care | |
| dc.subject | Practice guideline | |
| dc.subject | Review | |
| dc.subject | Screening | |
| dc.subject | Systematic review | |
| dc.subject | Thyroid disease | |
| dc.subject | Thyroiditis | |
| dc.subject | Thyrotoxicosis | |
| dc.title | Thyroid dysfunctions due to immune checkpoint inhibitors: A review | |
| dc.type | Review |
Files
Original bundle
1 - 1 of 1